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Background: Needle insertion pain associated with maintenance hemodialysis (HD) causes considerable stress on
HD patients with native arteriovenous fistula. Skin cooling has been suggested to modify pain sensitivity and
reduce needle insertion pain. Recently, a skin cooling device, named Mutsu-Senshi®, has been developed to
decrease local skin temperature to 21 °C smoothly and safely at the bedside. Therefore, we examined the
effectiveness of Mutsu-Senshi® in 4 HD centers in Japan.
Methods: We recruited adult patients receiving maintenance HD. After 1 week of HD in a conventional way,
Mutsu-Senshi® was additionally used before the start of every HD in the second week. The disinfected Mutsu-
Senshi® was placed on the disinfected access site before needle insertion to decrease skin temperature to 21 °C in
1 min. At the end of the second week, patients were asked to score relative changes in needle insertion pain on a
modified visual analog scale (VAS) on a tablet computer in private, from −100 indicating a marked increase in pain
intensity with Mutsu-Senshi® to +100 indicating a marked reduction in pain intensity with Mutsu-Senshi®. Results
were presented on scatter and box plots, with subgroup analyses according to age, sex, HD vintage, reasons for
end-stage renal disease, needle insertion site, the use of a lidocaine patch, and the diameter of needles used.
Finally, a multivariate logistic regression analysis was conducted to examine factors associated with the patients’
preferences for Mutsu-Senshi®.
Results: Of the 98 study participants with a native arteriovenous fistula (mean age 60.5 [standard deviation 13.8], men
66 %), 63 (64 %) rated Mutsu-Senshi® more favorably with modified VAS scores of >0. The median score was +29 with
an interquartile range from ±0 to +58. Subgroup analysis revealed that patients using dialysis needles with larger
diameters (15–17 gauge) tended to favor Mutsu-Senshi® compared with those using needles with a smaller diameter
(18 gauge). Needle diameter was also an independent factor associated with favoring Mutsu-Senshi®.
Conclusions: These multicenter prospective study data suggest that the majority of patients receiving maintenance
HD favor the use of the Mutsu-Senshi® skin cooling device before needle insertion. A group of patients using needles
with larger diameters may benefit more from Mutsu-Senshi®.
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The number of patients receiving dialysis for end-stage
renal disease (ESRD) has been increasing worldwide and
projected to more than double by 2030 [1]. Japan has
the second highest prevalence of dialysis for ESRD, next
to Taiwan, and the second largest number of patients
receiving dialysis, next to the USA [1]. The number of
Japanese patients receiving maintenance hemodialysis
(HD) was over 300,000 in 2012 [2]. Among different
types of vascular access available for HD, the native ar-
teriovenous fistula has been historically preferred in
Japan, accounting for nearly 90 % [3].
Pain associated with the insertion of dialysis needles
can cause considerable stress on HD patients [4]. In fact,
pain during needle insertion is the most common pa-
tient complaint regarding hemodialysis access [5]. Sev-
eral approaches have been developed to minimize needle
insertion pain, including buttonhole cannulation tech-
nique [6, 7], lidocaine-containing local anesthetic cream/
patches [8, 9], and lavender essential oil [10, 11]. How-
ever, their effects are variable and unpredictable.
Thermosensation and pain sensitivity are closely re-
lated. Studies have shown that skin temperatures over
43 °C and below 15 °C evoke a feeling of pain [12, 13].
However, within this range of 15 °C through 43 °C, lower
skin temperatures were associated with longer latencies
to pain sensation indicating decreased pain sensitivity
[14, 15]. Considering these findings, Daimon et al. tried
to control pain during needle insertion for HD by de-
creasing skin temperature to 20 °C with a cooling gel
[16]. Skin cooling was found to reduce needle insertion
pain significantly and as effectively as lidocaine patches.
With no adverse skin reactions related to the procedure,
the use of skin cooling was suggested to be more favor-
able for patients allergic to lidocaine patches.
A handy-sized device named Mutsu-Senshi® (Creative
Medical Engineering Co, Ishikawa, Japan) has recently been
developed to cool the skin (Fig. 1). In Japanese, “Mutsu”
means “painless,” while “Senshi” is a play on words mean-
ing both “centesis” and “fighter (for pain).” Mutsu-Senshi®
with a thermoelectric mechanism was shown to bring the
skin temperature down to around 21 °C in 1 min, without
causing significant changes in the diameter of dialysis ves-
sels [17]. It is expected that Mutsu-Senshi® can be used in
the clinical practice more smoothly and safely than the
method of using cooling gel.
However, Mutsu-Senshi® has never been formally eval-
uated for its effectiveness in multicenter studies. It isunknown what proportion of patients on HD favor the
use of this device in the real-world practice. Another
question is if there is any particular group of patients
who respond better to Mutsu-Senshi®. This would be
useful information for our clinical practice, allowing us
to recommend Mutsu-Senshi® for those who will benefit
most from this device. Therefore, this multicenter pro-
spective study was planned to assess the effectiveness of
the Mutsu-Senshi® skin cooling device in 4 dialysis cen-
ters in Japan.Methods
This study was registered with UMIN Clinical Trials
Registry, number UMIN000011802 [18]. After uploading
the study protocol, we modified it to simplify the process
and encourage a smooth operation of the study in the
real work environment. The points changed were as
follows: (i) observational periods for each patient were
shortened from 3 weeks (a normal week, a week using
Table 1 Baseline characteristics of study participants
Patients (n = 98)
Age (years, mean ± SD) 60.5 ± 13.8
Sex (men) 65 (66 %)
Hemodialysis vintage (years, median [IQR]) 4 [2–9]
Reasons for ESRD
Diabetes 46 (47 %)
Chronic glomerular nephritis 12 (12 %)
Nephrosclerosis 9 (9 %)
Polycystic kidney disease 5 (5 %)
Others 4 (4 %)
Unknown 22 (22 %)
Needle insertion site
Forearm 91 (93 %)
Upper arm 7 (7 %)
Use of lidocaine patch (yes) 40 (41 %)
Diameter of dialysis needle (gauge)
18 40 (41 %)
17 27 (28 %)
16 28 (29 %)
15 3 (3 %)
ESRD end-stage renal disease, IQR interquartile range, SD standard deviation
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(a normal week and a week using Mutsu-Senshi®); (ii)
patients were asked to evaluate the effect of Mutsu-
Senshi® only at the end of the second week, instead of after
every HD session; (iii) the pain scale was changed from a
commonly used absolute visual analog scale (VAS) for as-
sessment of pain intensity using numbers (e.g. 0–10) to a
modified VAS for assessment of relative changes in pain
intensity with Mutsu-Senshi®, as explained later.
Informed consent was obtained from individual pa-
tients. The study was approved by the institutional re-
view board of the University of Tokyo.
Study population
We conducted the study in 4 HD centers in Japan
(Medical Plaza Shinozaki, Tokyo; Asagaya-Suzuki Clinic,
Tokyo; Tokiwakai Group Tokiwa Hospital, Fukushima;
Akita City Hospital, Akita; and University of Tokyo
Hospital, Tokyo), during the period between January and
August, 2014. We recruited patients age 20 to 90 years
who were receiving maintenance HD. Exclusion criteria
included patients who may overreact to cold stimulation,
those with sensory disturbance in the limbs, those with
visual disturbance or hearing impairments, those unable
to communicate adequately with observers (e.g., demen-
tia), those with needle insertion troubles over the last 3
HD treatments, and those whom responsible doctors
consider as inappropriate participants.
Intervention
For the first week after entry into the study, patients re-
ceived HD in a conventional way, including needle inser-
tion by trained medical staff. For the second week,
Mutsu-Senshi® was additionally used, without changing
any other procedure conducted in the first week. Pa-
tients using lidocaine patches continued to use them in
the second week.
First, both the patient skin and the skin contacting
surface of the Mutsu-Senshi® were disinfected. After
switching on Mutsu-Senshi® and waiting until the
temperature of its skin contacting surface dropped to
21 °C and an indicator lamp was lit, the cooling device
was put on the access site before dialysis needle inser-
tion. Mutsu-Senshi® is designed to beep either when the
skin temperature reaches 21 °C or after 1 min of contact
with the skin; 1 min is considered sufficient to decrease
the skin temperature to around 21 °C for most users
[17]. Finally, dialysis needles were inserted in the same
way as the first week.
Assessment
At the end of the second week, we asked each partici-
pant to assess the effect of Mutsu-Senshi®. A modified
VAS was created for this purpose, scoring from −100indicating a marked increase in pain intensity with
Mutsu-Senshi® to +100 indicating a marked reduction in
pain intensity with Mutsu-Senshi®. The score ±0 indi-
cates that patients did not find any difference with or
without Mutsu-Senshi®. The participants were instructed
about the modified VAS score entry on a tablet com-
puter. No medical staff observed the process of entry to
reduce response bias. The results were transferred elec-
tronically to the Lifestyle Disease Coordinator Associ-
ation in Japan, anonymized, and then sent to the authors
for analysis in the end of the study. The Lifestyle Disease
Coordinator Association is totally independent of the
manufacturer of Mutsu-Senshi® as well as participating
HD centers.
Statistical analysis
Descriptive statistics were gathered for all eligible pa-
tients. Age was shown as mean and standard deviation
(SD), while HD vintage was expressed as median and
interquartile range (IQR). Categorical variables were
shown with number of patients and proportion. Distri-
bution of modified VAS was presented using a scatter
plot as well as a box plot with the scores of median,
IQR, minimum, and maximum. Scores outside of 1.5
times IQR were regarded as outliers and thus excluded
for the box plotting. Then, subgroup analysis was con-
ducted to identify any particular patient group benefiting
more from Mutsu-Senshi®. Patients were classified into 2
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HD vintage (<5 or ≥5 years), reason for ESRD (non-dia-
betes or diabetes), needle insertion site (forearm or
upper arm), the use of lidocaine patches, and diameter
of dialysis needles (15–17 gauge or 18 gauge). The cut-
off points for classification were determined such that
the number of patients in each subgroup was relatively
similar. Box plots were used for the individual subgroup,
and then a Wilcoxon rank sum test was conducted to
examine whether any predefined factor was associated
with increased preference for Mutsu-Senshi®. Finally, a
multivariate logistic analysis was conducted. The out-
come was modified VAS score >0 (vs. score ≤0), while
exposures were all the variables used for the aforemen-
tioned subgroup analysis. All data were analyzed using
Stata 14 software (Stata Corp, TX, USA). A P value of
<0.05 was considered statistically significant.
Results
Ninety-eight patients (mean age 60.5 [SD 13.8], men
66 %) participated in the study (Table 1). All patients
had native arteriovenous fistulas. All of them completed
pain assessment and reported no adverse effects associ-
ated with Mutsu-Senshi®. As shown in Fig. 2, modified
VAS scores were scattered from −100 to +100, and theFig. 2 Results of the modified visual analog scale presented as scatter andbox plot demonstrated the median score of +29 and IQR
from ±0 to +58. The proportion of patients scoring >0
(i.e., favoring Mutsu-Senshi®) was 64 % (63/98). In a sub-
group analysis (Fig. 3), there was no clear difference in
the preference for Mutsu-Senshi® between younger (<65)
and older (≥65) patients, between men and women, be-
tween shorter (<5 years) and longer (≥5 years) HD vin-
tages, between patients for whom diabetes was or was
not a cause of ESRD, and between the forearm and
upper arm for needle insertion. However, patients using
lidocaine patches tended to favor Mutsu-Senshi® com-
pared to those not using them (P = 0.089). Patients using
15–17-gauge needles demonstrated significantly stronger
preference for Mutsu-Senshi® than those using 18-gauge
needles (P = 0.006). In a multivariate logistic regres-
sion analysis (Table 2), needles with larger diameters
(15–17 gauge vs. 18 gauge) were significantly associ-
ated with favoring Mutsu-Senshi® (adjusted odd ratio
5.69, 95 % confidence interval [CI] 2.17–14.96). The
patients were further divided into 3 groups by needle
diameter (3 patients using 15 gauge were grouped
into those using 16 gauge): 15–16 gauge (n = 31),
17 gauge (n = 27), and 18 gauge (n = 40) in a multivariate
regression model. Compared with patients using 18-gauge
needles, the adjusted odds ratio in favor of Mutsu-Senshi®box plots
Fig. 3 Subgroup analyses for the assessment of Mutsu-Senshi® by factor and P value estimated by Wilcoxon rank sum test. ESRD end-stage renal
disease. *Median value was ±0 (the same as the lower side of an interquartile range)
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needles and 6.25 (95 % CI, 2.01–19.41) for those using 15-
or 16-gauge needles. These findings mean that, although
there was a significant difference between 15–17-gauge
and 18-gauge needles, no significant difference was ob-
served between 15–16-gauge and 17-gauge needles.Discussion
In this first prospective multicenter study, the Mutsu-
Senshi® skin cooling device was suggested to be ef-
fective in reducing needle insertion pain in patients
receiving HD. Mutsu-Senshi® was safely used in all of
the 98 patients without any complications, and 63
Table 2 Multivariate logistic regression analyses for favoring
Mutsu-Senshi® (modified visual analog scale >0)
Adjusted odds ratio 95 % CI P value
Age
<65 years Reference
≥65 years 1.20 0.47–3.07 0.705
Sex
Men Reference
Women 0.76 0.25–2.35 0.634
Dialysis vintage
<5 years Reference
≥5 years 1.27 0.49–3.27 0.624
Reason for ESRD
Non-diabetes Reference
Diabetes 0.63 0.23–1.75 0.375
Needle insertion site
Forearm Reference
Upper arm 0.70 0.13-3.76 0.674
Lidocaine patch use
No Reference
Yes 1.12 0.42-2.98 0.815
Needle diameter
18 gauge Reference
15–17 gauge 5.69 2.17–14.96 <0.001
CI confidence interval, ESRD end-stage renal disease
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dle insertion without skin cooling. We also found that
those using needles with larger diameter tended to
rate Mutsu-Senshi® more favorably, and this factor
was significant even in the multivariate regression
analysis.
Needle insertion pain is a considerable stress for pa-
tients receiving HD [4, 5]. It may be associated with de-
pressive symptoms and lower quality of life in patients
with HD [19]. Therefore, various methods have been
attempted to reduce needle insertion pain [6–11]. The
buttonhole technique has been expected to decrease
pain more effectively than the rope-ladder or rotating-
site cannulation technique [6], but a recent meta-
analysis concluded that no difference in cannulation pain
was found between the 2 techniques in randomized con-
trolled trials [7]. In contrast, lidocaine patches have been
shown to be effective in reducing pain [8, 9] and were
actually a popular pain management modality used by
40 of the 98 patients in our study population. However,
lidocaine patches frequently cause skin problems such as
pruritus and eczema. A Japanese study reported that
among 26 HD patients using lidocaine patches, 15 com-
plained of skin problems [20]. In our study, none of theparticipants reported skin problems associated with the
use of Mutsu-Senshi®. This is probably because the ex-
tent of skin cooling with Mutsu-Senshi® was mild, only
to 21 °C.
Sixty-four percent (63/98) of patients rated Mutsu-
Senshi® more favorably for pain relief, although the
median value of the modified VAS was not very large at
+29 (IQR from ±0 to +58). A univariate analysis sug-
gested that a subgroup of patients using lidocaine
patches tended to favor Mutsu-Senshi®. We speculate
that patients using lidocaine patches may be more sensi-
tive to pain, or more particular about pain control
methods, and therefore evaluated Mutsu-Senshi® more
favorably than those not using lidocaine patches. Our
findings also suggest that Mutsu-Senshi® can be used in
combination with lidocaine patches in the real-world
practice. In both univariate and multivariate analyses,
larger needle diameters were associated with a higher
preference for Mutsu-Senshi®. A potential explanation
would be that patients using needles with larger diameters
(15–17 gauge) might have had stronger needle fear.
Therefore, the use of Mutsu-Senshi® might have provided
them with greater relief than those using smaller diameter
(18 gauge) needles. However, no difference was observed
between 15–16-gauge and 17-gauge needles, which may
be explained by the small sample size or influence of con-
founding factors. Further study may be necessary to exam-
ine the association between needle diameter and the
usefulness of Mutsu-Senshi®.
This study has several strengths. First, patients were re-
cruited from 4 HD centers, increasing the generalizability
of the results. Second, all the prescribed conditions were
kept unchanged between the first and second weeks, ex-
cept for the additional use of Mutsu-Senshi®. In particular,
patients using lidocaine patches were allowed to continue
this use through the second week. Therefore, our findings
on the usefulness of Mutsu-Senshi® can be quickly ap-
plied to the current bedside practice without any
modification. Finally, the modified VAS was adminis-
tered while the medical staff were not observing. Pa-
tients may respond to the questionnaire differently if
they know they are being watched, probably leading
to a more favorable assessment of the new treatment.
By reducing response bias, we fairly examined the
usefulness of Mutsu-Senshi®.
However, this study also has limitations. First, an ideal
way of assessing the effect of Mutsu-Senshi® may be to
ask patients about their pain at the end of every HD ses-
sion, because pain severity can vary from day to day.
Calculating and comparing the average absolute pain
scores of several needle insertions with and without
Mutsu-Senshi® could have achieved even fairer assess-
ment of Mutsu-Senshi®. However, to recruit many pa-
tients and operate the study in the real-world clinical
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had to change the protocol to a single assessment com-
paring needle insertion pain with and without Mutsu-
Senshi® only 1 time at the end of the second week. For
this purpose, we had to modify a commonly used abso-
lute VAS to a comparative one, making it difficult to
compare the effectiveness of Mutsu-Senshi® with other
pain control modalities such as lidocaine patches [8, 9]
and lavender essential oil [10, 11]. Second, our study
population mostly included patients receiving HD for
1 year or longer. Therefore, the study participants might
be more tolerant of needle insertion pain than those re-
cently introduced to HD. It remains unknown whether
Mutsu-Senshi® is beneficial for patients who have under-
gone HD for a shorter time period and who may be
more sensitive to the pain. Finally, although the diameter
of dialysis needles was suggested to be an independent
factor for increased preference for Mutsu-Senshi®, this
finding might be influenced by unmeasured confounding
factors, such as skin thickness and mental health condi-
tions. Further studies are warranted to examine the use-
fulness of Mutsu-Senshi® and to identify the most
appropriate target population.
Conclusions
This multicenter prospective study suggested that the
Mutsu-Senshi® skin cooling device may help HD patients
with native arteriovenous fistula to better cope with nee-
dle insertion pain without causing skin complications.
The majority (64 %) of HD patients favored the use of
Mutsu-Senshi® before needle insertion. Patients using
needles with larger diameters may benefit more from
Mutsu-Senshi®.
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